H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $80 from $70 and keeps a Buy rating on the shares after the TRANSCEND pivotal trial of setmelanotide in hypothalamic obesity met the primary endpoint.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley
- Promising Phase 3 Results for Setmelanotide in Hypothalamic Obesity Drive Buy Rating
- BofA upgrades Rhythm Pharmaceuticals to Buy on ‘likely approvable’ data
- Rhythm Pharmaceuticals price target raised to $91 from $80 at Wells Fargo
- Rhythm Pharmaceuticals upgraded to Buy from Neutral at BofA